Latest market price
12.34
+0.04+0.33%
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -0.57 | Insider Own | — | Shs Outstand | 34.32M | Perf Week | -5.00% |
| Market Cap | 423.56M | Forward P/E | — | EPS next Y | -0.28 | Insider Trans | 0.00% | Shs Float | 25.57M | Perf Month | -2.83% |
| Enterprise Value | 439.56M | PEG | — | EPS next Q | -0.09 | Short Float | 3.47% | Perf Quarter | -12.73% | ||
| Income | -19.00M | P/S | 4.28 | EPS this Y | — | Short Ratio | 5.31 | Perf Half Y | -26.98% | ||
| Sales | 99.00M | P/B | 35.30 | EPS next Y | — | ROA | -19.71% | Short Interest | 886.23K | Perf YTD | -20.08% |
| Book/sh | 0.35 | P/C | 8.15 | EPS next 5Y | — | ROE | -119.68% | 52W High | 19.60 -37.04% | Perf Year | 25.15% |
| Cash/sh | 1.51 | P/FCF | — | EPS past 3/5Y | — | ROIC | -18.43% | 52W Low | 9.22 33.84% | Perf 3Y | 98.07% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 29.54% 19.52% | Gross Margin | 79.63% | Volatility | 4.00% 4.32% | Perf 5Y | -20.34% |
| Dividend TTM | — | EV/Sales | 4.44 | EPS Y/Y TTM | — | Oper. Margin | -15.26% | ATR (14) | 0.56 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 3.91 | Sales Y/Y TTM | 11.24% | Profit Margin | -19.34% | RSI (14) | 39.91 | Recom | 2.10 |
| Dividend Gr. 3/5Y | — | Current Ratio | 4.94 | EPS Q/Q | 30.77% | SMA20 | -3.49% | Beta | 1.93 | Target Price | 20.25 |
| Payout | 0.00% | Debt/Eq | 5.67 | Sales Q/Q | -4.17% | SMA50 | -9.57% | Rel Volume | 0.89 | Prev Close | 12.30 |
| Employees | 220 | LT Debt/Eq | 5.67 | Earnings | Nov 12 | SMA200 | -17.49% | Avg Volume | 135.30K | Price | 12.34 |
| IPO Date | Apr 22, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 17.37% 0.94% | Net Debt/EBITDA | — | Volume | 120,460 | Change | 0.33% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-17-26 | Initiated | KeyBanc | Overweight | $18 |
| Sep-15-26 | Reiterated | Raymond James | $21 | |
| Jul-23-26 | Initiated | Mizuho | Outperform | $22 |
| May-15-26 | Reiterated | HC Wainwright & Co. | Buy | $19 → $20 |
| Jan-27-26 | Reiterated | HC Wainwright & Co. | Buy | $19 |
| Dec-16-25 | Reiterated | UBS | Buy | $18 → $22 |
| Dec-09-25 | Reiterated | UBS | $18 | |
| Nov-05-25 | Reiterated | Leerink Partners | $19 | |
| Nov-05-25 | Reiterated | Cantor Fitzgerald | Overweight | $11 → $16 |
| Aug-14-24 | Reiterated | Wells Fargo | Overweight | $20 → $15 |
Latest News· Times ET
Oct-29-26
Oct-02-26
Oct-02-2606:15AM
Sep-18-26
Sep-18-2603:53AM
Sep-11-26
Sep-11-2604:06AM
Sep-10-26
Sep-04-26
Sep-02-26
Sep-01-26
Sep-01-2605:01PM
Aug-31-26
Aug-31-2604:05PM
Aug-17-26
Aug-14-26
Aug-12-26
Aug-11-26
Company
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99 | 100 | 80 | 65 | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 20 | 23 | 21 | 17 | — | — | — | — | |
| Gross Profit | 79 | 77 | 59 | 48 | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 65 | 66 | 57 | 55 | — | — | — | — | |
| Research and Development | 28 | 28 | 24 | 21 | — | — | — | — | |
| Other Operating Expense | 1 | 0 | 0 | -1 | — | — | — | — | |
| Operating Income | -16 | -16 | -22 | -27 | — | — | — | — | |
| Interest Expense | 8 | 7 | 9 | 9 | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 2 | 2 | 3 | 3 | — | — | — | — | |
| Net Income Before Taxes | -19 | -21 | -27 | -33 | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | 0 | — | — | — | — | |
| Consolidated Net Income | -19 | -21 | -27 | -33 | — | — | — | — | |
| Net Income From Continuing Operations | -19 | -21 | -27 | -33 | — | — | — | — | |
| Net Income | -19 | -21 | -27 | -33 | — | — | — | — | |
| EPS (Recurring) | -0.57 | -0.66 | -0.93 | -1.27 | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.57 | -0.66 | -0.93 | -1.27 | — | — | — | — | |
| EPS (Diluted) | -0.57 | -0.66 | -0.93 | -1.27 | — | — | — | — | |
| EBITDA | -12 | -12 | -17 | -23 | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.24 | 5.10 | 4.06 | 4.12 | — | — | — | — | |
| Gross Margin | 79.80 | 77.00 | 73.75 | 73.85 | — | — | — | — | |
| Operating Margin | -16.16 | -16.00 | -27.50 | -41.54 | — | — | — | — | |
| Net Margin | -19.19 | -21.00 | -33.75 | -50.77 | — | — | — | — | |
| Shares Outstanding | 34 | 33 | 29 | 26 | — | — | — | — | |
| Market Capitalization | 420 | 510 | 325 | 268 | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Morrell Martha | CHIEF MEDICAL OFFICER | Dec 15 '25 | Sale | 15.97 | 25,000 | 399,250 | 49,964 | Mar 04 |
| ORBIMED ADVISORS LLC | 10% Owner | May 14 '25 | Sale | 15.85 | 168,136 | 2,665,333 | 3,238,199 | May 16 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Feb 21 '25 | Sale | 13.72 | 78,334 | 1,074,844 | 81,993 | Feb 25 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Feb 12 '24 | Option Exercise | 0.03 | 50,000 | 1,300 | 160,327 | Feb 25 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Jan 31 '24 | Option Exercise | 0.03 | 52,810 | 1,373 | 96,480 | Feb 25 |
| KCK LTD. | 10% Owner | Feb 20 '25 | Sale | 9.40 | 5,270,845 | 49,545,943 | 0 | Feb 20 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Jan 30 '25 | Sale | 15.00 | 200 | 3,000 | 86,762 | Jan 31 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Jan 29 '25 | Sale | 15.00 | 100 | 1,500 | 86,962 | Jan 31 |
| Morrell Martha | CHIEF MEDICAL OFFICER | Jan 24 '25 | Sale | 15.01 | 3,200 | 48,032 | 87,062 | Jan 28 |
| KCK LTD. | 10% Owner | Oct 25 '24 | Sale | 5.45 | 223,991 | 1,221,042 | 5,270,845 | Oct 28 |
| KCK LTD. | 10% Owner | Oct 23 '24 | Sale | 6.02 | 147 | 885 | 5,494,836 | Oct 28 |
| KCK LTD. | 10% Owner | Oct 22 '24 | Sale | 6.09 | 4,082 | 24,853 | 5,494,983 | Oct 24 |
| KCK LTD. | 10% Owner | Oct 21 '24 | Sale | 6.10 | 3,720 | 22,679 | 5,499,065 | Oct 22 |
| KCK LTD. | 10% Owner | Oct 18 '24 | Sale | 6.29 | 4,878 | 30,692 | 5,502,785 | Oct 22 |
| KCK LTD. | 10% Owner | Oct 17 '24 | Sale | 6.28 | 3,294 | 20,686 | 5,507,663 | Oct 18 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.